Results 271 to 280 of about 1,300,697 (308)

sub art. 516

2009
Il commento analizza le problematiche connesse alle cose pignorabili in particolari circostanze di ...
openaire   +1 more source

CX-516 Cortex pharmaceuticals.

Current opinion in investigational drugs (London, England : 2000), 2003
CX-516 is one of a series of AMPA modulators under development by Cortex, in collaboration with Shire and Servier, for the potential treatment of Alzheimer's disease (AD), schizophrenia and mild cognitive impairment (MCI) [234221]. By June 2001, CX-516 was in phase II trials for both schizophrenia and attention deficit hyperactivity disorder (ADHD ...
openaire   +1 more source

Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme

Acta Neurologica Scandinavica, 2010
Torstein R Meling
exaly  

Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI

Investigational New Drugs, 2013
Kyung Won Kim, Jeong Min Lee, In Joon Lee   +2 more
exaly  

Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models

Epilepsy Research, 2017
Francesco G Salituro
exaly  

The Role of the Novel Exopolyphosphatase MT0516 in Mycobacterium tuberculosis Drug Tolerance and Persistence

PLoS ONE, 2011
Seema M Thayil, Petros C Karakousis
exaly  

Sophocles Ajax 516

Classical Philology, 1966
openaire   +1 more source

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Cancer Research and Treatment, 2016
Do-Youn Oh, Tae-Min Kim, Sae-Won Han
exaly  

Outline of IGCP 516

Journal of Asian Earth Sciences, 2012
Ken-Ichiro Hisada, Ian Metcalfe, Jin Xiaochi   +2 more
openaire   +1 more source

CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model

Investigational New Drugs, 2013
exaly